Open main menu
Home
Random
Recent changes
Special pages
Community portal
Preferences
About Wikipedia
Disclaimers
Incubator escapee wiki
Search
User menu
Talk
Dark mode
Contributions
Create account
Log in
Editing
Celecoxib
(section)
Warning:
You are not logged in. Your IP address will be publicly visible if you make any edits. If you
log in
or
create an account
, your edits will be attributed to your username, along with other benefits.
Anti-spam check. Do
not
fill this in!
== External links == * {{cite web | title=COX-2 Selective (includes Bextra, Celebrex, and Vioxx) and Non-Selective Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) | website=U.S. [[Food and Drug Administration]] (FDA) | date=15 July 2005 | url=https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/cox-2-selective-includes-bextra-celebrex-and-vioxx-and-non-selective-non-steroidal-anti-inflammatory | archive-url=https://web.archive.org/web/20190928144031/https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/cox-2-selective-includes-bextra-celebrex-and-vioxx-and-non-selective-non-steroidal-anti-inflammatory | url-status=dead | archive-date=28 September 2019 }} * {{cite web | title=FDA Approves Labeling Supplement for Celebrex (celecoxib) | website=U.S. [[Food and Drug Administration]] (FDA) | date=28 June 2018 | url=https://www.fda.gov/drugs/drug-safety-and-availability/cder-statement-fda-approves-labeling-supplement-celebrex-celecoxib }} {{Chemotherapeutic agents}} {{Anti-inflammatory and antirheumatic products}} {{Analgesics}} {{Prostanoid signaling modulators}} {{Portal bar | Medicine}} {{Authority control}} [[Category:Antineoplastic drugs]] [[Category:COX-2 inhibitors]] [[Category:CYP2D6 inhibitors]] [[Category:Nonsteroidal anti-inflammatory drugs]] [[Category:Drugs developed by Pfizer]] [[Category:Pyrazoles]] [[Category:Sulfonamides]] [[Category:Trifluoromethyl compounds]] [[Category:Wikipedia medicine articles ready to translate]] [[Category:4-Tolyl compounds]]
Edit summary
(Briefly describe your changes)
By publishing changes, you agree to the
Terms of Use
, and you irrevocably agree to release your contribution under the
CC BY-SA 4.0 License
and the
GFDL
. You agree that a hyperlink or URL is sufficient attribution under the Creative Commons license.
Cancel
Editing help
(opens in new window)